Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease:The Gut and Obesity Asia initiative

被引:0
作者
Panyavee Pitisuttithum [1 ]
Wah-Kheong Chan [2 ]
George Boon-Bee Goh [3 ]
Jian-Gao Fan [4 ]
Myeong Jun Song [5 ]
Phunchai Charatcharoenwitthaya [6 ]
Ajay Duseja [7 ]
Yock-Young Dan [8 ]
Kento Imajo [9 ]
Atsushi Nakajima [9 ]
Khek-Yu Ho [8 ]
Khean-Lee Goh [2 ]
Vincent Wai-Sun Wong [10 ]
Sombat Treeprasertsuk [1 ]
机构
[1] Department of Medicine and Therapeutics, The Chinese University of Hong Kong
[2] Department of Medicine, Faculty of Medicine, Chulalongkorn University
[3] Department of Medicine, University of Malaya
[4] Department of Gastroenterology & Hepatology, Singapore General Hospital
[5] Department of Gastroenterology, Shanghai Jiao Tong University School of Medicine
[6] Department of Internal Medicine, The Catholic University of Korea
[7] Division of Gastroenterology, Faculty of Medicine Siriraj Hospital, Mahidol University
[8] Department of Hepatology, Post Graduate Institute of Medical Education and Research
[9] Department of Medicine, National University of Singapore
[10] Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine
关键词
Nonalcoholic fatty liver disease; Gamma glutamyl transferase; QRISK; Cardiovascular risk; Gut and Obesity in Asia;
D O I
暂无
中图分类号
R575.5 [肝代谢障碍]; R54 [心脏、血管(循环系)疾病];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Gamma-glutamyl transferase(GGT) is associated with the risk of cardiovascular disease(CVD) in the general population.AIM To identify the association of baseline GGT level and QRISK2 score among patients with biopsy-proven nonalcoholic fatty liver disease(NAFLD).METHODS This was a retrospective study involving 1535 biopsy-proven NAFLD patients from 10 Asian centers in 8 countries using data collected by the Gut and Obesity in Asia(referred to as "GO ASIA") workgroup. All patients with available baseline GGT levels and all 16 variables for the QRISK2 calculation(QRISK2-2017; developed by researchers at the United Kingdom National Health Service;https://qrisk.org/2017/; 10-year cardiovascular risk estimation) were included and compared to healthy controls with the same age, sex, and ethnicity. Relative risk was reported. QRISK2 score > 10% was defined as the high-CVD-risk group.Fibrosis stages 3 and 4(F3 and F4) were considered advanced fibrosis.RESULTS A total of 1122 patients(73%) had complete data and were included in the final analysis; 314(28%) had advanced fibrosis. The median age(interquartile range[IQR]) of the study population was 53(44-60) years, 532(47.4%) were females,and 492(43.9%) were of Chinese ethnicity. The median 10-year CVD risk(IQR)was 5.9%(2.6-10.9), and the median relative risk of CVD over 10 years(IQR) was1.65(1.13-2.2) compared to healthy individuals with the same age, sex, and ethnicity. The high-CVD-risk group was significantly older than the low-risk group(median [IQR]: 63 [59-67] vs 49 [41-55] years; P < 0.001). Higher fibrosis stages in biopsy-proven NAFLD patients brought a significantly higher CVD risk(P < 0.001). Median GGT level was not different between the two groups(GGT[U/L]: Median [IQR], high risk 60 [37-113] vs low risk 66 [38-103], P = 0.56). There was no correlation between baseline GGT level and 10-year CVD risk based on the QRISK2 score(r = 0.02).CONCLUSION The CVD risk of NAFLD patients is higher than that of healthy individuals.Baseline GGT level cannot predict CVD risk in NAFLD patients. However,advanced fibrosis is a predictor of a high CVD risk.
引用
收藏
页码:2416 / 2426
页数:11
相关论文
共 23 条
[1]   NAFLD fibrosis score:A prognostic predictor for mortality and liver complications among NAFLD patients [J].
Sombat Treeprasertsuk ;
Einar Bjrnsson ;
Felicity Enders ;
Sompongse Suwanwalaikorn ;
Keith D Lindor .
World Journal of Gastroenterology, 2013, (08) :1219-1229
[2]  
Association Between γ-Glutamyltransferase Level and Cardiovascular or All-Cause Mortality in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis[J] . Ping Yang,Peng Wu,Xing Liu,Jian Feng,Shuzhan Zheng,Yan Wang,Zhongcai Fan.Angiology . 2019 (9)
[3]   Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative [J].
Chan, W-K. ;
Treeprasertsuk, S. ;
Imajo, K. ;
Nakajima, A. ;
Seki, Y. ;
Kasama, K. ;
Kakizaki, S. ;
Fan, J-G. ;
Song, M. J. ;
Yoon, S. K. ;
Dan, Y-Y. ;
Lesmana, L. ;
Ho, K-Y. ;
Goh, K-L. ;
Wong, V. W-S. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (06) :816-825
[4]  
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study[J] . Hippisley-Cox Julia,Coupland Carol,Brindle Peter.BMJ (Clinical research ed.) . 2017 (may2)
[5]  
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis[J] . Dulai Parambir S,Singh Siddharth,Patel Janki,Soni Meera,Prokop Larry J,Younossi Zobair,Sebastiani Giada,Ekstedt Mattias,Hagstrom Hannes,Nasr Patrik,Stal Per,Wong Vincent Wai-Sun,Kechagias Stergios,Hultcrantz Rolf,Loomba Rohit.Hepatology (Baltimore, Md.) . 2017 (5)
[6]  
Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk[J] . Gerald Koenig,Stephanie Seneff,Ralf Lichtinghagen.Disease Markers . 2015
[7]  
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease[J] . Paul Angulo,David E. Kleiner,Sanne Dam-Larsen,Leon A. Adams,Einar S. Bjornsson,Phunchai Charatcharoenwitthaya,Peter R. Mills,Jill C. Keach,Heather D. Lafferty,Alisha Stahler,Svanhildur Haflidadottir,Flemming Bendtsen.Gastroenterology . 2015 (2)
[8]   Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease [J].
Chen, Ying ;
Xu, Min ;
Wang, Tiange ;
Sun, Jichao ;
Sun, Wanwan ;
Xu, Baihui ;
Huang, Xiaolin ;
Xu, Yu ;
Lu, Jieli ;
Li, Xiaoying ;
Wang, Weiqing ;
Bi, Yufang ;
Ning, Guang .
ATHEROSCLEROSIS, 2015, 241 (01) :145-150
[9]   Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease [J].
Sonmez, Alper ;
Nikolic, Dragana ;
Dogru, Teoman ;
Ercin, Cemal Nunri ;
Genc, Halil ;
Cesur, Mustafa ;
Tapan, Serkan ;
Karslioglu, Yildirim ;
Montalto, Giuseppe ;
Banach, Maciej ;
Toth, Peter P. ;
Bagci, Sait ;
Rizzo, Manfredi .
JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (04) :576-582
[10]  
Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies[J] . Setor K. Kunutsor,Tanefa A. Apekey,Hassan Khan.Atherosclerosis . 2014 (1)